Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase-positive non‐small cell lung cancer

• Hoofdauteurs: Joy C. Hsu (Auteur), Felix Jaminion (Auteur), Elena Guerini (Auteur), Bogdana Balas (Auteur), Walter Bordogna (Auteur), Peter N. Morcos (Auteur), Nicolas Frey (Auteur)
• Formaat: Boek
• Gepubliceerd in: Wiley, 2021-11-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK‐positive non‐small cell lung cancer. Population pharmacokinetic (PK) models were developed for alectinib and its major active metabolite M4 using phase I/II PK data in crizotinib‐failed patients (N = 13...